News
DRMA
0.4108
+4.50%
0.0177
Maxim Group Sticks to Their Buy Rating for Dermata Therapeutics (DRMA)
TipRanks · 11h ago
Weekly Report: what happened at DRMA last week (0318-0322)?
Weekly Report · 3d ago
Dermata Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Dermata Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 21 cents per share. The average analyst rating on the shares is "buy" The company's shares had fallen by 34.4% this quarter.
Reuters · 6d ago
DRMA Stock Earnings: Dermata Therapeutics Reported Results for Q4 2023
Dermata Therapeutics reported earnings per share of -21 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. DermataTherapeutics just reported results for the 4th quarter of 2020. The stock is down 1.7% today.
Investorplace · 6d ago
Dermata Therapeutics Inc: Annual report
Press release · 6d ago
Dermata Therapeutics GAAP EPS of -$2.67 beats by $1.55
Dermata Therapeutics, Inc. FY GAAP EPS of -$2.67 beats by $1.55. As of December 31, 2023, the Company had $7.4 million in cash and cash equivalents. The company is expected to report its results on March 21, 2024.
Seeking Alpha · 03/21 20:47
Dermata Therapeutics FY23 EPS $(2.67) Vs $(13.92) YoY
As of December 31, 2023, the Company had $7.4 million in cash and cash equivalents. The Company expects its current cash resources to be sufficient to fund operations into the third quarter of 2024. Research and development expenses were $4.1 million for the year ended 2023.
Benzinga · 03/21 20:23
Dermata Therapeutics: Unveiling Recent Financial Performance
TipRanks · 03/21 20:23
Weekly Report: what happened at DRMA last week (0311-0315)?
Weekly Report · 03/18 10:23
Weekly Report: what happened at DRMA last week (0304-0308)?
Weekly Report · 03/11 10:21
Dermata Therapeutics Inc: Other preliminary proxy statements
Press release · 03/04 16:04
Weekly Report: what happened at DRMA last week (0226-0301)?
Weekly Report · 03/04 10:24
Weekly Report: what happened at DRMA last week (0219-0223)?
Weekly Report · 02/26 10:31
Weekly Report: what happened at DRMA last week (0212-0216)?
Weekly Report · 02/19 10:32
Weekly Report: what happened at DRMA last week (0205-0209)?
Weekly Report · 02/12 10:26
Weekly Report: what happened at DRMA last week (0129-0202)?
Weekly Report · 02/05 10:31
Weekly Report: what happened at DRMA last week (0122-0126)?
Weekly Report · 01/29 10:24
Weekly Report: what happened at DRMA last week (0115-0119)?
Weekly Report · 01/22 10:27
Dermata Therapeutics Inc: [Cover]SEC-generated letter
Press release · 01/17 18:03
Dermata Therapeutics Inc: Correspondence
Press release · 01/17 18:03
More
Webull provides a variety of real-time DRMA stock news. You can receive the latest news about Dermata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.